Mechanism of Nardostachyos Radix et Rhizoma and Corydalis Rhizoma on Atrial Fibrillation Based on Network Pharmacology

Ting MAO; Jing-chun ZHANG; Bei LIU; Shan ZHANG; Yu-zhen AI

doi:10.13422/j.cnki.syfjx.20201203

您当前的位置：

首页 >

文章列表页 >

Mechanism of Nardostachyos Radix et Rhizoma and Corydalis Rhizoma on Atrial Fibrillation Based on Network Pharmacology

Data Mining | 更新时间：2020-08-11

- Mechanism of Nardostachyos Radix et Rhizoma and Corydalis Rhizoma on Atrial Fibrillation Based on Network Pharmacology
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 26, Issue 13, Pages: 190-198(2020)
- 作者机构：
  
  中国中医科学院西苑医院，心血管病研究所，北京 100091
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20201203
  CLC： R2-0;R22;R285.5;R284
- Published Online：14 March 2020，
  
  Published：05 July 2020
- 稿件说明：
移动端阅览
毛婷,张京春,刘蓓等.基于网络药理学探讨甘松-延胡索组方治疗房颤的作用机制[J].中国实验方剂学杂志,2020,26(13):190-198.

MAO Ting,ZHANG Jing-chun,LIU Bei,et al.Mechanism of Nardostachyos Radix et Rhizoma and Corydalis Rhizoma on Atrial Fibrillation Based on Network Pharmacology[J].Chinese Journal of Experimental Traditional Medical Formulae,2020,26(13):190-198.
毛婷,张京春,刘蓓等.基于网络药理学探讨甘松-延胡索组方治疗房颤的作用机制[J].中国实验方剂学杂志,2020,26(13):190-198. DOI： 10.13422/j.cnki.syfjx.20201203.

MAO Ting,ZHANG Jing-chun,LIU Bei,et al.Mechanism of Nardostachyos Radix et Rhizoma and Corydalis Rhizoma on Atrial Fibrillation Based on Network Pharmacology[J].Chinese Journal of Experimental Traditional Medical Formulae,2020,26(13):190-198. DOI： 10.13422/j.cnki.syfjx.20201203.

摘要

目的

通过网络药理学预测甘松-延胡索组方治疗房颤的作用靶点及信号通路，进一步探讨潜在作用机制。

方法

采用中药系统药理学分析平台（TCMSP）筛选甘松-延胡索组方的活性成分并预测其作用靶点，构建活性成分-预测靶点网络。通过人类孟德尔遗传综合数据库（OMIM），治疗靶点数据库（TTD），基因组注释数据库（Genecards）检索房颤的潜在靶点，采用蛋白质相互作用网络数据库（STRING 11.0）获取房颤靶点蛋白相互作用的网络，通过Cytoscape 3.7.1软件对数据进行可视化分析，构建房颤靶点的蛋白互作网络。将甘松-延胡索组方的预测靶点映射至房颤靶点集合上，其交集靶点即为甘松-延胡索组方治疗房颤的潜在靶点。然后运用功能注释生物信息学分析平台（DAVID）数据库对甘松-延胡索组方治疗房颤的潜在靶点进行生物功能及信号通路富集分析。再通过Cytoscape 3.7.1软件构建甘松-延胡索组方治疗房颤的活性成分-潜在靶点-信号通路网络。

结果

筛选出51个甘松-延胡索组方的活性成分，预测出甘松-延胡索组方治疗房颤的潜在靶点18个，主要通过白细胞介素-6（IL-6），钠通道蛋白亚型5

（SCN5A），肿瘤坏死因子（TNF），内皮源性一氧化氮合酶（NOS3），电压依赖性钾通道亚型H2（KCNH2），胶原

1（I）链（COL1A1），维甲酸受体RXR-

（RXRA），组织因子（F3），

1B肾上腺素能受体（ADRA1B）等靶蛋白，以及环磷酸酸鸟苷（cGMP）/蛋白激酶G（PKG）信号通路，磷脂酰肌醇-3激酶（PI3K）/蛋白激酶B（Akt）信号通路，癌症中的转录失调，钙信号通路，心肌细胞中的肾上腺素信号等信号通路发挥治疗房颤的作用。

结论

甘松-延胡索组方是基于多成分、多靶点、多通路治疗房颤，为后续开展实验研究以进一步阐释其作用机制提供了科学依据。

Abstract

Objective

To investigate the mechanism of Nardostachyos Radix et Rhizoma and Corydalis Rhizoma in treatment of atrial fibrillation by predicting targets and signaling pathways based on network pharmacology.

Method

The traditional Chinese medicine system platform (TCMSP) database was used to screen out active components of Nardostachyos Radix et Rhizoma and Corydalis Rhizoma

predict targets

and construct the active component-predicted target network.Through the Online Mendelian Inheritance in Man (OMIM)

Therapeutic Target Database (TTD)

and Genecards databases

potential target information of atrial fibrillation was retrieved.STRING 11.0 database was used to obtain the protein-protein interaction data of relevant targets

and the results were visualized by Cytoscape 3.7.1 software to construct protein-protein interaction network relating to atrial fibrillation.The predicted targets of Nardostachyos Radix et Rhizoma and Corydalis Rhizoma were mapped to the potential targets of atrial fibrillation.The intersection targets were the potential targets for the treatment of atrial fibrillation with Nardostachyos Radix et Rhizoma and Corydalis Rhizoma.Then

Visualization and Integrated Discovery (DAVID)

a database for annotation

was used to analyze biological functions and pathways of the potential targets of Nardostachyos Radix et Rhizoma and Corydalis Rhizoma in the treatment of atrial fibrillation.Finally

Cytoscape3.7.1 software was utilized to construct active component-potential target-signal pathway network of Nardostachyos Radix et Rhizoma and Corydalis Rhizoma in treatment of atrial fibrillation.

Result

Totally 51 active components of Nardostachyos Radix et Rhizoma and Corydalis Rhizoma were screened out

and 18 potential targets for the treatment of atrial fibrillation with Nardostachyos Radix et Rhizoma and Corydalis Rhizoma were predicted.The effect was mainly correlated with the regulation of interleukin-6 (IL-6)

sodium channel protein type 5 subunit alpha (SCN5A)

tumor necrosis factor (TNF)

nitric-oxide synthase

endothelial (NOS3)

potassium voltage-gated channel subfamily hmember 2 (KCNH2)

collagen alpha-1(I) chain (COL1A1)

retinoic acid receptor RXR-alpha (RXRA)

tissue factor (F3)

alpha-1B adrenergic receptor (ADRA1B) and other target proteins

cyclic guanosine monophosphate (cGMP)/cGMP-dependent protein kinase G (PKG) signaling pathway

phosphatidylinositol-3-kinases (PI3K)/protein kinase B (Akt) signaling pathway

transcriptional disorders in cancer

calcium signaling pathways

and adrenergic signals in cardiomyocytes.

Conclusion

Nardostachyos Radix et Rhizoma and Corydalis Rhizoma treat atrial fibrillation based on multiple components

multiple targets and multiple channels

and provide a scientific basis for subsequent experimental studies for further explainning its mechanism of action.

关键词

Keywords

references

杨涛 , 胡郎吉 , 葛郁芝 . 中药甘松抗心律失常作用及其电生理机制研究 [J]. 现代诊断与治疗 , 2008 , 19 ( 5 ): 276 - 278 .

张萍 , 徐凤芹 , 马晓昌 , 等 . 延胡索治疗快速性心律失常的研究进展 [J]. 中国中西医结合杂志 , 2012 , 32 ( 5 ): 713 - 716 .

陈可冀 , 蒋跃绒 , 谢元华 . 病证结合治疗观的过去和现在 [J]. 中国中西医结合杂志 , 2011 , 31 ( 4 ): 437 - 443 .

马胜兴 , 陈可冀 , 王荣金 . 延胡索碱治疗过早搏动的临床研究 [J]. 中华心血管病杂志 , 1983 , 11 ( 1 ): 6 - 9 .

国家药典委员会．中华人民共和国药典(一部) [S]．北京 : 中国医药科技出版社， 2010 ．

吴以岭 . 络病学 [M]. 4版 . 北京 : 中国科学技术出版社 , 2004 ： 280 - 283 ．

雷舒雁 . 基于数据挖掘的从肝论治心律失常组方用药规律研究 [D]. 北京 : 北京中医药大学 , 2017 .

谢朝霞 . 中药治疗房颤的系统评价 [D]. 北京 : 北京中医药大学 , 2013 .

俞晓婷 . 心房颤动中西医研究进展 [J]. 中西医结合心脑血管病杂志 , 2015 , 13 ( 16 ): 1847 - 1849 .

张雨 , 李恒 , 李克宁 , 等 . 复方中药网络药理学的研究进展 [J]. 中成药 , 2018 , 40 ( 7 ): 1584 - 1588 .

RU J , LI P , WANG J , et al . TCMSP:a database of systems pharmacology for drug discovery from herbal medicines [J]. J Cheminform , 2014 , 6 ( 1 ): 13 .

吴纯伟 , 路丽 , 梁生旺 , 等 . 药物靶标预测技术在中药网络药理学中的应用 [J]. 中国中药杂志 , 2016 , 41 ( 3 ): 377 - 382 .

SZKLARCZYK D , FRANCESCHINI A , KUHN M , et al . The STRING database in 2011:functional interaction networks of proteins,globally integrated and scored [J]. Nucleic Acids Res , 2011 , 39 ( D1 ): D561 - D568 .

周自强 , 胡大一 , 陈捷 , 等 . 中国心房颤动现状的流行病学研究 [J]. 中华内科杂志 , 2004 , 43 ( 7 ): 15 - 18 .

SPOSATO L A , CIPRIANO L E , SAPOSNIK G , et al . Diagnosis of atrial fibrillation after stroke and transient ischaemic attack:a systematic review and meta-analysis [J]. Lancet Neurol , 2015 , 14 ( 4 ): 377 - 387 ．

GOETTE A , STAACK T , ROCKEN C , et al . Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation [J]. J Am Coll Cardiol , 2000 , 35 ( 6 ): 1669 - 1677 .

FRUSTACI A , CHIMENTI C , BELLOCCI F , et al . Histological substrate of atrial biopsies in patients with lone atrial fibrillation [J]. Circulation , 1997 , 96 ( 4 ): 1180 - 1184 .

南笑珂 , 张鲁 , 罗琳 , 等 . 中药甘松化学成分与药理作用的研究进展 [J]. 中国现代中药 , 2018 , 20 ( 10 ): 1312 - 1318 .

王红 , 田明 , 王淼 , 等 . 延胡索现代药理及临床研究进展 [J]. 中医药学报 , 2010 , 38 ( 6 ): 108 - 111 .

ANSELMI A , POSSATI G , GAUDINO M . Postoperative inflammatory reaction and atrial fibrillation:simple correlation or causation [J]. Ann Thorac Surg , 2009 , 88 ( 1 ): 326 - 333 ．

GUO Y , LIP G Y , APOSTOLAKIS S . Inflammation in atrial fibrillation [J]. J Am Coll Cardiol , 2012 , 60 ( 22 ) : 2263 - 2270 ．

YU T , ZHU W , GU B , et al . Simvastatin attenuates sympathetic hyperinnervation to prevent atrial fibrillation during the postmyocardial infarction remodeling process [J]. J Appl Physiol , 2012 , 113 ( 12 ) : 1937 - 1944 ．

胡培静 , 杜媛 , 王娅 , 等 . 钠通道SCN5A突变体R104W的构建及验证 [J]．西安交通大学学报:医学版 , 2015 , 36 ( 4 ): 435 - 438,443 ．

ELLINOR P T , NAM E G , SHEA M A , et al . Cardiac sodium channel mutation in atrial fibrillation [J]. Heart Rhythm , 2008 , 5 ( 1 ): 99 - 105 ．

KROGH-MADSEN T , ABBOTT G W , CHRISTINI D J . Effects of electrical and structural remodeling on atrial fibrillation maintenance:a simulation study [J]. PLoS Comput Biol , 2012 , 8 ( 2 ): e1002390 .

CALVO D , FILGUEIRAS-RAMA D , JALIFE J . Mechanisms and drug development in atrial fibrillation [J]. Pharmacol Rev , 2018 , 70 ( 3 ): 505 - 525 .

ISHII Y , SCHUESSLER R B , GAYNOR S L , et al . Inflammation of atrium after cardiac surgery is associated with inhomogeneity of atrial conduction and atrial fibrillation [J]. Circulation , 2005 , 111 : 2881 - 2888 .

SHIROSHITA-TAKESHITA A , BRUNDEL B J , LAVOIE J , et al . Prednisone prevents atrial fibrillation promotion by atrial tachycardia remodeling in dogs [J]. Cardiovasc Res , 2006 , 69 : 865 - 875 .

汤宝鹏 , 甘天翊 , 许国荣 , 等 . 慢性心房颤动心房肌间质纤维化的分子机制研究 [J]. 中华心律失常学杂志 , 2009 , 13 ( 5 ): 369 - 372 ．

马世玉 , 张敏州 , 马金 . 纤维化引起心房电传导功能障碍导致心房颤动的机制及其抗纤维化治疗 [J]. 医学综述 , 2017 , 23 ( 14 ): 2794 - 2799 .

GUO Y , LIP G Y , APOSTOLAKIS S . Inflammatory biomarkers and atrial fibrillation:potential role of inflammatory pathways in the pathogenesis of atrial fibrillation-induced thromboembolism [J]. Curr Vasc Pharmacol , 2015 , 13 ( 2 ): 192 - 201 .

ICHISHIMA K , YAMAMOTO S , IWAMOTO T , et al . Alpha-Adrenoceptor-mediated depletion of phosphatidylinositol 4,5-bisphosphate inhibits activation of volume-regulated anion channels in mouse ventricular myocytes [J]. Br J Pharmacol , 2010 , 161 ( 1 ): 193 - 206 .

UCHI J O , SASAKI H , MORIMOTO S , et al . Interaction of alpha1-adrenoceptor subtypes with different G proteins induces opposite effects on cardiac L-type Ca 2+ channel [J]. Circ Res , 2008 , 102 ( 11 ): 1378 - 1388 .

CHOISY S C , HANCOX J C , ARBERRY L A , et al . Evidence for a novel K + channel modulated by alpha(1A)-adrenoceptors in cardiac myocytes [J]. Mol Pharmacol , 2004 , 66 ( 3 ): 735 - 748 .

HAMMOND J , BALLIGAND J L . Nitric oxide synthase and cyclic GMP signaling in cardiac myocytes:from contractility to remodeling [J]. J Mol Cell Cardiol , 2012 , 52 ( 2 ): 330 - 340 .

OTAKE H , SUZUKI H , HONDA T , et al . Influences of autonomic nervous system on atrial arrhythmogenic substrates and the incidence of atrial fibrillation in diabetic heart [J]. Int Heart J , 2009 , 50 ( 5 ): 627 - 641 .

PRETORIUS L , DU X J , WOODCOCK E A , et al . Reduced phosphoinositide 3-kinase (p110 α ) activation increases the susceptibility to atrial fibrillation [J]. Am J Pathol , 2009 , 175 ( 3 ): 998 - 1009 .

STAVRAKIS S , SCHERLAG B J , FAN Y , et al . Inhibition of atrial fibrillation by low-level vagus nerve stimulation:the role of the nitric oxide signaling pathway [J]. J Interv Card Electr , 2013 , 36 ( 3 ): 199 - 208 .

SINGHAL R , CHANG S L , CHONG E , et al . Colchicine suppresses atrial fibrillation in failing heart [J]. Int J Cardiol , 2014 , 176 ( 3 ): 651 - 660 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Analysis on Pharmacodynamic Material Basis and Mechanism of Famous Classical Formula Renshen Wuweizi Tang in Treatment of Spleen and Lung Qi Deficiency Syndrome

Study on Mechanism of Action of Matrine in Treatment of Inflammatory Bowel Disease Based on Zebrafish Model and Network Pharmacology

Mechanism of Chenpi Huoxiangtang Against Diarrhea： Based on Network Pharmacology and Experimental Verification

Mechanism of Xianglian Huazhuo Prescription Against Chronic Atrophic Gastritis Based on Network Pharmacology and Experimental Verification

Mechanism of Dendrobium huoshanense in Treatment of Gastric Ulcer： Based on Network Pharmacology and in Vivo Experiment

Related Author

LI Shanshan

ZHONG Yute

XIANG Xiaomei

KANG Wei

ZHOU Shufan

WANG Ping

XU Haiyu

CHEN Linzhen

Related Institution

Key Laboratory for Research and Evaluation of Traditional Chinese Medicine， National Medical Products Administration，Institute of Chinese Materia Medica， China Academy of Chinese Medical Sciences

Liaoning Herbapex Pharmaceutical（Group） Co. Ltd.

Beijing Key Laboratory of Traditional Chinese Medicine（TCM） Quality Evaluation， Beijing University of Chinese Medicine

School of TCM， Beijing University of Chinese Medicine

National Institutes for Food and Drug Control

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰